+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Typhoid Fever - Pipeline Review, H2 2020

  • ID: 5137259
  • Drug Pipelines
  • July 2020
  • Region: Global
  • 53 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • Etna Biotech Srl
  • Eubiologics Co Ltd
  • GlaxoSmithKline Plc
  • Indian Immunologicals Ltd
  • Prokarium Ltd
  • Protein Potential LLC
  • MORE
Typhoid Fever - Pipeline Review, H2 2020

Summary

The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Typhoid Fever - Pipeline Review, H2 2020, provides an overview of the Typhoid Fever (Infectious Disease) pipeline landscape.

Typhoid fever is an infection that causes diarrhea and a rash. It is most commonly due to a type of bacterium called Salmonella typhi (S. typhi). Symptoms include abdominal tenderness, agitation, chills, delirium, hallucinations, severe fatigue and weakness. Treatment includes antibiotics and supportive therapy.

Report Highlights

The publisher's Pharmaceutical and Healthcare latest pipeline guide Typhoid Fever - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Typhoid Fever (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Typhoid Fever (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Typhoid Fever and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 3, 2, 2, 4, 1 and 1 respectively. Similarly, the Universities portfolio in Phase III, Preclinical and Unknown stages comprises 1, 2 and 1 molecules, respectively.

Typhoid Fever (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Typhoid Fever (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Typhoid Fever (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Typhoid Fever (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Typhoid Fever (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Typhoid Fever (Infectious Disease)
Reasons to Buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Typhoid Fever (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Typhoid Fever (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Etna Biotech Srl
  • Eubiologics Co Ltd
  • GlaxoSmithKline Plc
  • Indian Immunologicals Ltd
  • Prokarium Ltd
  • Protein Potential LLC
  • MORE
  • Introduction
  • Report Coverage
  • Typhoid Fever - Overview
  • Typhoid Fever - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Pipeline by Universities/Institutes
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Typhoid Fever - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Typhoid Fever - Companies Involved in Therapeutics Development
  • Etna Biotech Srl
  • Eubiologics Co Ltd
  • GlaxoSmithKline Plc
  • Indian Immunologicals Ltd
  • Matrivax Research & Development Corp
  • Novo Medi Sciences Pvt Ltd
  • Prokarium Ltd
  • Protein Potential LLC
  • Sanofi Pasteur SA
  • Shantha Biotechnics Pvt Ltd
  • Walvax Biotechnology Co Ltd
  • Typhoid Fever - Drug Profiles
(paratyphoid (bivalent) + typhoid) vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
(paratyphoid + typhoid) vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
(rotavirus (virus like particle) + typhiod) vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
(shigella + typhoid) (Bivalent) vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
(Streptococcal pneumonia + typhoid) vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • EUC-002 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • infectious disease vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Typhella - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Typhoid Fever - Dormant Projects
  • Typhoid Fever - Discontinued Products
  • Typhoid Fever - Product Development Milestones
  • Featured News & Press Releases
  • Appendix
List of Tables
  • Number of Products under Development for Typhoid Fever, H2 2020
  • Number of Products under Development by Companies, H2 2020
  • Number of Products under Development by Universities/Institutes, H2 2020
  • Products under Development by Companies, H2 2020
  • Products under Development by Universities/Institutes, H2 2020
  • Number of Products by Stage and Target, H2 2020
  • Number of Products by Stage and Route of Administration, H2 2020
  • Number of Products by Stage and Molecule Type, H2 2020
  • Typhoid Fever - Pipeline by Etna Biotech Srl, H2 2020
  • Typhoid Fever - Pipeline by Eubiologics Co Ltd, H2 2020
  • Typhoid Fever - Pipeline by GlaxoSmithKline Plc, H2 2020
  • Typhoid Fever - Pipeline by Indian Immunologicals Ltd, H2 2020
  • Typhoid Fever - Pipeline by Matrivax Research & Development Corp, H2 2020
  • Typhoid Fever - Pipeline by Novo Medi Sciences Pvt Ltd, H2 2020
  • Typhoid Fever - Pipeline by Prokarium Ltd, H2 2020
  • Typhoid Fever - Pipeline by Protein Potential LLC, H2 2020
  • Typhoid Fever - Pipeline by Sanofi Pasteur SA, H2 2020
  • Typhoid Fever - Pipeline by Shantha Biotechnics Pvt Ltd, H2 2020
  • Typhoid Fever - Pipeline by Walvax Biotechnology Co Ltd, H2 2020
  • Typhoid Fever - Dormant Projects, H2 2020
  • Typhoid Fever - Discontinued Products, H2 2020
List of Figures
  • Number of Products under Development for Typhoid Fever, H2 2020
  • Number of Products under Development by Companies, H2 2020
  • Number of Products under Development by Universities/Institutes, H2 2020
  • Number of Products by Targets, H2 2020
  • Number of Products by Stage and Targets, H2 2020
  • Number of Products by Routes of Administration, H2 2020
  • Number of Products by Stage and Routes of Administration, H2 2020
  • Number of Products by Molecule Types, H2 2020
  • Number of Products by Stage and Molecule Types, H2 2020
Note: Product cover images may vary from those shown
3 of 3
  • Etna Biotech Srl
  • Eubiologics Co Ltd
  • GlaxoSmithKline Plc
  • Indian Immunologicals Ltd
  • Matrivax Research & Development Corp
  • Novo Medi Sciences Pvt Ltd
  • Prokarium Ltd
  • Protein Potential LLC
  • Sanofi Pasteur SA
  • Shantha Biotechnics Pvt Ltd
  • Walvax Biotechnology Co Ltd
Note: Product cover images may vary from those shown
Adroll
adroll